IMG 7289

Drug Profile

IMG 7289

Alternative Names: IMG-7289; LSD1 inhibitor - Imago BioSciences

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Imago BioSciences
  • Class Antineoplastics
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I Myelofibrosis

Most Recent Events

  • 19 Jul 2017 Phase-II clinical trials in Acute myeloid leukaemia (Combination therapy, Late-stage disease) in Australia (PO)
  • 19 Jul 2017 Phase-II clinical trials in Acute myeloid leukaemia (Late-stage disease, Monotherapy) in Australia (PO)
  • 19 Jul 2017 Phase-II clinical trials in Myelodysplastic syndromes (Combination therapy, Late-stage disease) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top